Seven Fleet Capital Management LP Purchases New Shares in Krystal Biotech, Inc. $KRYS

Seven Fleet Capital Management LP purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,000 shares of the company’s stock, valued at approximately $986,000. Krystal Biotech accounts for about 0.7% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 24th largest position.

A number of other institutional investors have also added to or reduced their stakes in KRYS. Greenline Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the 4th quarter worth about $34,000. Sound Income Strategies LLC boosted its stake in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after acquiring an additional 127 shares in the last quarter. UMB Bank n.a. boosted its stake in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares in the last quarter. Global Retirement Partners LLC grew its holdings in Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the period. Finally, Danske Bank A S purchased a new stake in Krystal Biotech in the third quarter worth about $35,000. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

KRYS has been the subject of several recent research reports. Citigroup lifted their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Guggenheim raised their price objective on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday. TD Cowen boosted their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday. Finally, HC Wainwright increased their target price on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $340.56.

Krystal Biotech Stock Up 1.9%

NASDAQ:KRYS opened at $348.06 on Friday. The company’s 50 day moving average price is $294.24 and its 200-day moving average price is $271.55. Krystal Biotech, Inc. has a 52 week low of $130.17 and a 52 week high of $356.50. The stock has a market cap of $10.26 billion, a price-to-earnings ratio of 46.53 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.